Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bit Digital Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Bit Digital Inc trades at $1.67 (market cap $599.01M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 66.6× Bit Digital Inc's market cap. Which is the better fit depends on your goals.
| ALNY | BTBT | |
|---|---|---|
Market Cap | $39.89B | $599.01M |
Sector | Health | Technology |
52-Week High | $491.22 | $4.22 |
52-Week Low | $278.09 | $1.27 |
Enterprise Value | $38.15B | $888.32M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BTBT trades at $1.69, showing slight positive momentum with a 0.6% daily gain, but faces a bearish technical outlook with 15 sell signals versus 3 buys. The company reported a net loss of $80.32 million in 2025, with revenue of $113.56 million, and has missed earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
The outlook remains challenging due to persistent losses and negative profit margins, though analyst consensus is unanimously bullish with 2 buy ratings. Key risks include execution challenges in AI infrastructure investments, reliance on financing for cash flow, and sensitivity to cryptocurrency market volatility impacting its strategic asset holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
